New cream for mild to moderate eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new cream called JYP0066 for people with mild-to-moderate atopic dermatitis (eczema). It aims to see if the cream safely reduces itching and skin inflammation. It might help if you have tried other creams and still have symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 75 years old and weigh at least 40 kg (about 88 pounds).
- Your eczema must be mild or moderate, covering 3% to 20% of your body (but not counting your scalp, face, or genitals).
- You must have had eczema for at least 6 months and meet the standard Williams criteria for atopic dermatitis.
- If you are able to have children, you must agree to use highly effective birth control during the study and for 1 month after the last dose.
- You cannot have used certain eczema treatments recently, like JAK inhibitors or biologic injections (e.g., dupilumab), and you must avoid strong CYP3A4 medications and live vaccines during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet called JYP0061 for people with moderate to severe atopic dermatitis (eczema) that has lasted at least a year. It aims to see if the drug is safe and effective in reducing symptoms.
This study tests a new cream (CMS-D001) for people with moderate to severe eczema. Participants will receive either the study cream or a placebo (a cream with no active ingredient) to see if it helps reduce symptoms like itching and redness.
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
This study tests an investigational cream for moderate to severe eczema. It helps see if the cream reduces symptoms like itching and skin inflammation.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.